Key US Advisory Committee to Cast Ballots on Modifying Baby Hepatitis B Vaccine Advisory
Following a hold-up and an unusually contentious gathering, a federal vaccine advisory panel was set to cast ballots on Friday concerning altering the long-held guideline that all newborns be immunized against hepatitis B.
Fiery Exchange and a Delayed Ballot
The opening session of the assembly on Thursday was defined by intense argument over restricting access to the hepatitis B vaccine for infants and a resolution to postpone the decision by a day to provide committee members extra time to examine the language. The panel, which guides the Centers for Disease Control and Prevention on immunization practices, had put off the vote twice in the past.
“Is there any concrete proof of harm of giving this immunization before 30 days? Or is this conjecture?” inquired one adviser.
In answer, another participant stated, “There is limited evidence about the enduring danger.”
Existing Recommendations and Potential Impact
The vaccine is currently recommended for every newborn within 24 hours of delivery to prevent infection of hepatitis B, which can result in significant hepatic injury. It has been given to more than a billion persons for in excess of thirty years.
The Georgia assembly provided no fresh data of harms caused by the vaccine. Specialists note any modification to the current hepatitis B immunization timeline could have profound and widespread repercussions for infant and child health in the United States.
Panel Composition and Recent Changes
The consultative group can only provide advice to the director of the CDC. The committee's composition has undergone changes recently, with the declaration that the committee’s most recent chair would leave for an official role and be replaced by a heart specialist who has been questioning of other inoculations.
The board includes multiple immunization doubters who align with a aim to revamp – and potentially, in some cases, eliminate – traditional immunization guidelines.